Arpit Chhabra: The True Challenge and Opportunity of Building Theranostics Programs
4h agoen
From the article
Arpit Chhabra, Co-Founder of Bridge Oncology, shared a post on LinkedIn: “The Biggest Bottleneck in Theranostics Isn’t the Isotope. Over the past several months, as I’ve been leading the development […]
Continue reading on OncoDailyYou might also wanna read
Tracing evolution of vaccine for cancer, malaria
Harvard T.H. Chan School of Public Health·1d ago
The purification challenge behind engineered antibody drugs for cancer
This article explores the complex science and engineering behind purifying pharmaceutical molecules at industrial scale, focusing on bispeci
newscientist.com·4h ago
India’s Generic Pharma Industry Is Sitting on a Formulation Data Time Bomb
ChemCopilot·7d ago
Molecular glue approach doubles survival time for pancreatic cancer patients in breakthrough trial
Chemical biologist Gregory Verdine developed a novel approach to fighting cancer by using "molecular glues" to bind disease-causing proteins
pasadenastarnews.com·1mo ago
Towards mRNA therapeutics 2.0
doi.org·4d ago
Rapid Drug Susceptibility Testing for Tuberculosis Using Raman-Deuterium Isotope Probing
This article presents a novel method for rapid drug susceptibility testing (DST) of Mycobacterium tuberculosis using Raman-deuterium isotope
go.acs.org·4d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.